BPC-157 and GHK-Cu: What the evidence actually shows in 2026

Peptides - short chains of amino acids, the body's tiny protein building blocks that act as signaling molecules - are among the most talked-about topics in regenerative medicine. Two stand out: BPC-157 and GHK-Cu. One is hyped as a "miracle healer" for tendons and ligaments, the other is considered the gold standard for skin regeneration. But what does the scientific evidence actually say? A look at the research landscape in 2025/2026 reveals a nuanced picture.

BPC-157: Big hype, few completed human trials

Body Protective Compound-157 (BPC-157) has been promoted for years in sports and biohacking circles as a regenerative wonder drug. The reality: As of early 2026, not a single randomized controlled trial (RCT) for applications involving bones, muscles, tendons, and joints has been completed and published in humans. Recent review articles (papers that summarize the current state of research) also emphasize that the available evidence comes almost exclusively from animal studies (rats, pigs) and case reports, a classic "evidence gap" that has been repeatedly documented in media reporting on the marketing of unapproved peptides.

A glimmer of hope: Since February 2026, Hudson Biotech has been running the first Phase 2 trial (a mid-stage human study), randomized, double-blind, and placebo-controlled, meaning neither participants nor doctors know who receives the actual substance and who receives an inactive placebo. The trial is registered on ClinicalTrials.gov as NCT07437547 ("BPC 157 for Acute Hamstring Muscle Strain Repair") and additionally documented via the Veeva Clinical Trial Vault. This trial is investigating BPC-157 for accelerated healing of acute Grade II hamstring strains (moderate muscle tears in the back of the thigh) in 120 participants. Results are expected no earlier than 2027. An actual peer-reviewed original study on safety now exists: the pilot study "Safety of Intravenous Infusion of BPC157 in Humans" by E. Lee and K. Burgess (indexed on PubMed, PMID 40131143). It reports on two healthy adults with good tolerability of intravenous BPC-157, though without any efficacy claims. A blog post on wellfounded.health merely cites this publication as a secondary source.

GHK-Cu: Broad research, but no FDA approval

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is the far better-studied substance. This naturally occurring copper peptide made of three amino acid building blocks has been researched for over 50 years. Multiple clinical trials demonstrate positive effects on skin elasticity, collagen synthesis, and wound healing with topical application (applied directly to the skin). On top of that, a clearly registered ongoing Phase 2 program exists: on ClinicalTrials.gov you can find the recruiting study NCT07437586 ("Topical GHK-Cu Gel for Acute Skin Wound Healing", also sponsored by Hudson Biotech).

Despite the solid data, GHK-Cu is not FDA-approved for any medical use (indication). The evidence primarily covers topical application (applied directly to the skin); long-term safety data for injectable forms remain lacking. As with BPC-157, distribution as a "research chemical" operates in a regulatory gray area.

Bottom line: Two peptides, two worlds of evidence

The comparison shows: GHK-Cu has decades of research, albeit with gaps, and reproducible results for skin regeneration. BPC-157, by contrast, still lives primarily on animal data and anecdotal reports; the first real human trial is only now underway. Neither substance is FDA-approved, and neither should be confused with approved medications. If you want to learn more, visit the peptide pages on BPC-157 and GHK-Cu for details on mechanisms and current research status.

Not medical advice: This article is for educational and scientific information purposes only and does not replace professional medical consultation.